Lixisenatide · source year
6 selected, source-linked Lixisenatide records carrying a 2020 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
6 selected records.
3 represented types.
6 distinct public records.
Cited chronology
Regulatory
DailyMed lists Structured Product Labeling version 15 for the reviewed Lixisenatide label family with a published date of 2020-12-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory
DailyMed lists Structured Product Labeling version 14 for the reviewed Lixisenatide label family with a published date of 2020-07-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02640118 at 2026-07-30T20:27:50.520Z. Its registry update date was 2020-05-07, and PeptideScanner's reviewed identity mapping was lixisenatide.
Source: ClinicalTrials.gov ↗
Regulatory
DailyMed lists Structured Product Labeling version 13 for the reviewed Lixisenatide label family with a published date of 2020-03-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 31873867 at 2026-07-30T20:33:08.013Z. PubMed recorded a metadata revision date of 2020-02-26 and an Entrez history date of 2019-12-25. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory
DailyMed lists Structured Product Labeling version 12 for the reviewed Lixisenatide label family with a published date of 2020-01-24. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.